

Monitoring Drug Therapy
Live Virtual Course | Date: May 8, 2026

Sponsored by



Friday, May 8, 2026		
Time (Mountain Time)	Topic	Presenter(s)
8:00-8:15 am	Welcome and Introductions	<i>Dr. Andrew Mackin</i>
8:15-8:45 am	Immunosuppressive Therapy <ul style="list-style-type: none"> • Understand the difference between pharmacokinetic and pharmacodynamic monitoring. • Understand the need for the pharmacokinetic monitoring of cyclosporine (and in certain circumstances, mycophenolate mofetil and leflunomide) when administering systemic immunosuppressive therapy. • Understand the value of pharmacodynamic monitoring for all immunosuppressive agents. 	<i>Dr. Andrew Mackin</i>
8:45-9:15 am	Anticonvulsant Therapy <ul style="list-style-type: none"> • Review recommended therapeutic drug monitoring protocols for the most commonly used anticonvulsant medications in canine and feline patients. • Identify appropriate blood work recommendations for patients receiving anticonvulsant therapy. • Interpret anticonvulsant drug monitoring results and apply this information to clinical decision-making for individual patients. 	<i>Dr. Missy Carpentier</i>
9:15-9:45 am	Drug Therapy for Patients with Liver Disease <ul style="list-style-type: none"> • Understand how drugs are cleared by the liver. • Understand the most common tests to identify liver injury and whether these are predictive of hepatic drug clearance. • Understand the best choices for treatment of specific conditions in animals with liver injury. 	<i>Dr. Mark Papich</i>
9:45-10:00 am	Break	
10:00-11:00 am	Drug Therapy for Patients with Renal Disease <ul style="list-style-type: none"> • Understand how drugs are cleared by the kidney. • Discuss when and how to amend dose in patients with renal dysfunction. • Review recommended drug monitoring protocols for commonly used medications for kidney disease. 	<i>Dr. JD Foster</i> <i>Dr. Jessica Quimby</i>
11:00-12:00 pm	Panel Discussion <ul style="list-style-type: none"> • Discuss immunosuppressive therapy. • Explore topics related to anticonvulsant therapy. • Explore questions specific to drug therapy for patients with liver disease. 	<i>Dr. Missy Carpentier</i> <i>Dr. Mark Papich</i> <i>Dr. JD Foster</i> <i>Dr. Jessica Quimby</i> <i>Moderator: Dr. Andrew Mackin</i>

Monitoring Drug Therapy
Live Virtual Course | Date: May 8, 2026

Sponsored by



Friday, May 8, 2026 (cont.)

Time (Mountain Time)	Topic	Presenter(s)
12:00-1:00 pm	Lunch Break	
1:00-1:30 pm	<p>Monitoring Trilostane Therapy</p> <ul style="list-style-type: none"> • Understand the available data on cortisol monitoring. • List the strengths and weaknesses of trilostane monitoring approaches. • Determine when the monitoring approach needs to be adjusted for a specific patient. 	<i>Dr. Patty Lathan</i>
1:30-2:00 pm	<p>Monitoring Mineralocorticoid Therapy in Addisons</p> <ul style="list-style-type: none"> • Gain familiarity with the original field trials that led to current DOCP dosing guidelines. • Understand the benefits and limitations of electrolyte monitoring for assessing mineralocorticoid status. • Use current evidence to design safe, cost-effective, and physiologically appropriate dosing protocols for DOCP. 	<i>Dr. Daniel Langlois</i>
2:00-3:00 pm	<p>Antimicrobial Therapy/Avoiding Antimicrobial Resistance</p> <ul style="list-style-type: none"> • Describe recent breakpoint revisions and the clinical implications of the susceptible dose dependent category. • Interpret susceptibility reports in the context of pharmacokinetics, pharmacodynamics, and infection site. • Apply pharmacologic principles to select the most appropriate available therapy for extensively resistant infections when optimal options are limited. 	<i>Dr. Cooper Brookshire</i>
3:00-3:15 pm	Break	
3:15-4:15 pm	<p>Pharmacogenomics</p> <ul style="list-style-type: none"> • Describe when it is appropriate to determine a dog's MDR1 genotype prior to drug therapy. • Describe when it is appropriate to determine a cat's MDR1 genotype prior to drug therapy. • Describe when it is appropriate to determine a dog's DEPOHGEN genotype prior to surgery. 	<i>Dr. Katrina Mealey</i>

Monitoring Drug Therapy
Live Virtual Course | Date: May 8, 2026

Sponsored by



Friday, May 8, 2026 (cont.)

Time (Mountain Time)	Topic	Presenter(s)
4:15-5:15 pm	<p>Panel Discussion</p> <ul style="list-style-type: none"> • Explore topics related to monitoring mineralocorticoid therapy in Addisons. • Discuss antimicrobial therapy and topics related to avoiding antimicrobial resistance. • Explore issues with pharmacogenomics. 	<p><i>Dr. Patty Lathan</i> <i>Dr. Daniel Langlois</i> <i>Dr. Cooper Brookshire</i> <i>Dr. Katrina Mealey</i></p> <p><i>Moderator: Dr. Andrew Mackin</i></p>